IC
ImmuCell Corporation
ICCC · NASDAQ
$9.75 +1.56% (+$0.15)
1M -4.00%
Market Cap $86.8M
P/E Ratio 110.30x
Div. Yield -
ROE 2.68%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Strong
7/9Valuation
34 /100
Fair P/E 110.30x
EV/EBITDA 25.57x
P/S 2.83x
Growth
67 /100
Growing Rev. growth 14.19%
Book val. growth 3.79%
EPS growth N/A
Profitability
61 /100
Moderate Gross margin 40.32%
Net margin 2.57%
Op. margin 12.60%
Quality
32 /100
Poor ROIC 8.14%
ROE 2.68%
ROA 1.69%
Debt
80 /100
Low Debt/Equity 0.40x
Current ratio 4.75x
Int. coverage 2.66x
Stability
31 /100
Unstable Beta 0.55x
Rev. volatility 30.69%
EPS volatility 112.13%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ICCC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
F. Olivier Te Boekhorst
Employees
73
Headquarters
Portland
Upcoming events
12 NOV
Earnings
Upcoming earnings report